News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actinium Pharmaceuticals, Inc. Webinar to Discuss Iomab™-B at 11AM EDT Today



10/15/2013 10:01:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Oct. 15, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is hosting an online webinar today at 11:00 AM EDT to discuss current progress with Iomab-B. Iomab-B has completed a Phase I/II trial in bone marrow conditioning for hematopoietic stem cell transplantation (HSCT) in relapsed and/or refractory elderly acute myeloid leukemia (AML) patients demonstrating a clear survival benefit which is potentially curative.

Webcast / Telecast Information:

Date: Tuesday, October 15, 2013

Time: 11:00 AM EDT

US Dial-in (Toll-free): 1-877-407-0789

International Dial-in: 1-201-689-8562

For the live and archived webcast, please visit the Investors page on the Actinium website at www.actiniumpharmaceuticals.com or https://viavid.webcasts.com/starthere.jsp?ei=1023654

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies. The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contact:

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
E-mail: ir@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES